114 related articles for article (PubMed ID: 33496632)
21. Re: Association of Inpatient Use of Angiotensin-converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients with Hypertension Hospitalized with COVID-19.
Rouette J; Suissa K; Azoulay L
Epidemiology; 2020 Nov; 31(6):e52-e53. PubMed ID: 33555810
[No Abstract] [Full Text] [Related]
22. Two hits to the renin-angiotensin system may play a key role in severe COVID-19.
Tseng YH; Yang RC; Lu TS
Kaohsiung J Med Sci; 2020 Jun; 36(6):389-392. PubMed ID: 32492292
[TBL] [Abstract][Full Text] [Related]
23. A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).
Talreja H; Tan J; Dawes M; Supershad S; Rabindranath K; Fisher J; Valappil S; van der Merwe V; Wong L; van der Merwe W; Paton J
N Z Med J; 2020 Apr; 133(1512):85-87. PubMed ID: 32242182
[TBL] [Abstract][Full Text] [Related]
24. [Renin-angiotensin-aldosterone system : brief history and questions related to the COVID-19 pandemic].
Valdes-Socin H; Jouret F; Vroonen L; Scheen AJ; Lancellotti P
Rev Med Liege; 2020 Sup; 75(S1):123-129. PubMed ID: 33211434
[TBL] [Abstract][Full Text] [Related]
25. Inhibitors of the renin-angiotensin-aldosterone system and COVID-19 in critically ill elderly patients.
Jung C; Bruno RR; Wernly B; Joannidis M; Oeyen S; Zafeiridis T; Marsh B; Andersen FH; Moreno R; Fernandes AM; Artigas A; Pinto BB; Schefold J; Wolff G; Kelm M; De Lange DW; Guidet B; Flaatten H; Fjølner J;
Eur Heart J Cardiovasc Pharmacother; 2021 Jan; 7(1):76-77. PubMed ID: 32645153
[No Abstract] [Full Text] [Related]
26. A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19.
Usman MS; Siddiqi TJ; Khan MS; Ahmed A; Ali SS; Michos ED; Hall ME; Krasuski RA; Greene SJ; Butler J; Alkhouli M
Am J Cardiol; 2020 Sep; 130():159-161. PubMed ID: 32624189
[No Abstract] [Full Text] [Related]
27. Are angiotensin-converting enzyme inhibitors/angiotensin receptor blockers associated with reduced severe acute respiratory syndrome coronavirus 2 infections and improved outcomes, and does race matter?
Armato J; DeFronzo RA; Chiu ST; Rider D; Ruby R
Diabetes Obes Metab; 2022 Dec; 24(12):2465-2468. PubMed ID: 35971756
[No Abstract] [Full Text] [Related]
28. Renin-angiotensin-aldosterone system inhibitors to treat COVID-19?
Henry RA
CMAJ; 2020 Jun; 192(26):E728. PubMed ID: 32601254
[No Abstract] [Full Text] [Related]
29. Reply: ACE Inhibitors and Angiotensin II Receptor Blockers May Have Different Impact on Prognosis of COVID-19.
Amat-Santos IJ; Santos-Martinez S; López-Otero D; Delgado-Arana JR; San Román JA
J Am Coll Cardiol; 2020 Oct; 76(17):2042. PubMed ID: 33092743
[No Abstract] [Full Text] [Related]
30. Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients.
Baral R; White M; Vassiliou VS
Curr Atheroscler Rep; 2020 Aug; 22(10):61. PubMed ID: 32830286
[TBL] [Abstract][Full Text] [Related]
31. Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and COVID-19: Demonstrating the Actionability of Real-World Evidence.
Hennessy S; Cohen JB
Am J Hypertens; 2021 Apr; 34(4):327-329. PubMed ID: 33156920
[No Abstract] [Full Text] [Related]
32. Covid-19: the renin-angiotensin system imbalance hypothesis.
Lanza K; Perez LG; Costa LB; Cordeiro TM; Palmeira VA; Ribeiro VT; Simões E Silva AC
Clin Sci (Lond); 2020 Jun; 134(11):1259-1264. PubMed ID: 32507883
[TBL] [Abstract][Full Text] [Related]
33. Pharmacovigilance in patients with diabetes: A data-driven analysis identifying specific RAS antagonists with adverse pulmonary safety profiles that have implications for COVID-19 morbidity and mortality.
Stafford EG; Riviere JE; Xu X; Kawakami J; Wyckoff GJ; Jaberi-Douraki M
J Am Pharm Assoc (2003); 2020; 60(6):e145-e152. PubMed ID: 32561317
[TBL] [Abstract][Full Text] [Related]
34. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.
Reynolds HR; Adhikari S; Pulgarin C; Troxel AB; Iturrate E; Johnson SB; Hausvater A; Newman JD; Berger JS; Bangalore S; Katz SD; Fishman GI; Kunichoff D; Chen Y; Ogedegbe G; Hochman JS
N Engl J Med; 2020 Jun; 382(25):2441-2448. PubMed ID: 32356628
[TBL] [Abstract][Full Text] [Related]
35. Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers.
Gersh FL
Mayo Clin Proc; 2020 Jul; 95(7):1552-1553. PubMed ID: 32622456
[No Abstract] [Full Text] [Related]
36. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies: comment.
De Cauwer H
Intern Emerg Med; 2020 Nov; 15(8):1581-1582. PubMed ID: 32564289
[No Abstract] [Full Text] [Related]
37. Do the Meta-Analyses Provide a Clean Bill of Health to the Use of Renin-angiotensin System Inhibitors in Coronavirus Disease 2019 (COVID-19)?
Kow CS; Hasan SS
Clin Infect Dis; 2021 Jul; 73(1):164-165. PubMed ID: 32770237
[No Abstract] [Full Text] [Related]
38. [COVID-19 and cardiovascular diseases].
Chazova IE; Mironova OI
Ter Arkh; 2020 Oct; 92(9):4-7. PubMed ID: 33346424
[TBL] [Abstract][Full Text] [Related]
39. ACE Inhibitors and Angiotensin II Receptor Blockers May Have Different Impact on Prognosis of COVID-19.
Wang Y; Tse G; Li G; Lip GYH; Liu T
J Am Coll Cardiol; 2020 Oct; 76(17):2041. PubMed ID: 33092742
[No Abstract] [Full Text] [Related]
40. The other possible mechanism of the benefits of RAAS inhibition in the athogenesis of COVID-19.
Gupta N; Patel K; Gupta R
Clin Cardiol; 2020 Dec; 43(12):1349. PubMed ID: 33174213
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
